These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36775959)

  • 1. An update of the pharmacological treatment options for generalized myasthenia gravis in adults with anti-acetylcholine receptor antibodies.
    Riley TR; Douglas JS; Wang C; Bowser KM
    Am J Health Syst Pharm; 2023 May; 80(11):652-662. PubMed ID: 36775959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
    Heo YA
    CNS Drugs; 2023 May; 37(5):467-473. PubMed ID: 37000339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.
    Dos Santos JBR; Gomes RM; da Silva MRR
    Expert Rev Clin Immunol; 2022 Sep; 18(9):879-888. PubMed ID: 35892247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efgartigimod: First Approval.
    Heo YA
    Drugs; 2022 Feb; 82(3):341-348. PubMed ID: 35179720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
    van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
    Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future.
    Crisafulli S; Boccanegra B; Carollo M; Bottani E; Mantuano P; Trifirò G; De Luca A
    CNS Drugs; 2024 Jan; 38(1):15-32. PubMed ID: 38212553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod.
    Sorrenti B; Laurini C; Bosco L; Strano CMM; Scarlato M; Gastaldi M; Filippi M; Previtali SC; Falzone YM
    Eur J Neurol; 2024 Jul; 31(7):e16306. PubMed ID: 38716750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis.
    Bril V; Silvestri NJ; Barnett-Tapia C
    Prim Care Companion CNS Disord; 2022 May; 24(3):. PubMed ID: 35621832
    [No Abstract]   [Full Text] [Related]  

  • 11. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
    Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
    Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective.
    Suzuki S; Uzawa A; Murai H
    Expert Rev Clin Immunol; 2022 Dec; 18(12):1207-1215. PubMed ID: 36227228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
    Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
    Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
    Saccà F; Barnett C; Vu T; Peric S; Phillips GA; Zhao S; Qi CZ; Gelinas D; Chiroli S; Verschuuren JJGM
    J Neurol; 2023 Apr; 270(4):2096-2105. PubMed ID: 36598575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
    Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF;
    J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment considerations in myasthenia gravis for the pregnant patient.
    Gilhus NE
    Expert Rev Neurother; 2023 Feb; 23(2):169-177. PubMed ID: 36786092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.
    Singer M; Khella S; Bird S; McIntosh P; Paudyal B; Wadhwani A; Quinn C; Karam C
    Muscle Nerve; 2024 Jan; 69(1):87-92. PubMed ID: 37990374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Myasthenia in adults, children, and adolescents: what's new?].
    Stascheit F; Della Marina A; Meisel A
    Nervenarzt; 2023 Jun; 94(6):501-509. PubMed ID: 36995386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscle autoantibodies in myasthenia gravis: beyond diagnosis?
    Meriggioli MN; Sanders DB
    Expert Rev Clin Immunol; 2012 Jul; 8(5):427-38. PubMed ID: 22882218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
    Di Stefano V; Alonge P; Rini N; Militello M; Lupica A; Torrente A; Brighina F
    J Neurol; 2024 Jan; 271(1):254-262. PubMed ID: 37682316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.